C
hemotherapy is the single mostimportant factor in the improved survival observed during the last several decades in patients with osteosarcoma; its inclusion in the care of these patients is uncontroversial. In the current study, Xu and colleagues [9] examine the timing of adjuvant chemotherapy in pelvic osteosarcoma and found that neoadjuvant chemotherapy did not alter overall survival or local recurrence compared to early surgery. This result is consistent with similar investigations [3, [5] [6] [7] . The conclusion of clinical relevance is that neoadjuvant chemotherapy is an option, not a requirement, for patients with pelvic osteosarcoma.
A key potential benefit of chemotherapy prior to surgical resection (neoadjuvant chemotherapy) is that it allows for an assessment of disease response, and as such, is potentially an important predictor of overall survival. Currently, because effective options for patients who respond poorly are limited, this information is mainly useful for prognosis, but has not lead to improved survival in these high-risk patients.
The broader issue in this paper is that of deviation from a commonly accepted treatment. In cancer, it is easy to justify more-aggressive management, driven by the allure of improved survival and the comforting appearance of active intervention. It can be exceedingly challenging to advocate for a less-intensive or non-standard approach, which may provide a functional or quality-of-life benefit but carries only the assertion that it is "not inferior" to the standard care. Those who were in conflict with the legacy of the Halsted radical mastectomy know dearly the difficulty in deescalating treatment of a known lethal disease process. Fisher and colleagues [4] eventually performed a definitive clinical trial in favor of less-morbid surgical intervention without decreasing survival or increasing recurrence in breast cancer. In their classic paper, albeit with less methodologic rigor than Fisher and colleagues [4] , Simon and colleagues advocated for similar reasons that limb salvage surgery was oncologically equivalent to amputation in osteosarcoma of the distal femur [8] . Ironically, it is from the earliest experience with limb salvage that the paradigm of neoadjuvant chemotherapy was established, the same paradigm brought into question by the authors of the current study.
Where Do We Need To Go?
The advent of limb salvage in sarcoma is historically linked to the concept of neoadjuvant treatment [8] . At the time, it was considered a necessity, given the weeks to months required to procure a custom implant or allograft. Modern limb-salvage surgery, for the most part, does not require an extensive waiting period as 
The sarcoma community of patients, providers, and scientists continue to work, wait, and dream of more-effective systemic treatments. Until then, we generally use chemotherapy because we cannot know with certainty that a patient presenting with osteosarcoma is free from microscopic metastases. The rationale for neoadjuvant chemotherapy is that in the subset of patients for whom it is effective and who present with micrometastases, neoadjuvant treatment may treat and limit further micrometastases, and it also can inform both further treatment choices (based on whether the main tumor seems to respond to the chemotherapeutic agents or not), as well as prognosis. But neoadjuvant therapy may cause harm in a small, but real, minority of patients whose tumors are localized, without micrometastasis, but resistant to the therapeutic agents in question. In these patients, neoadjuvant therapy simply delays the definitive resection, during which time the lethal tumor continues to shed malignant cells into the bloodstream as anthracyclines and platins circulate ineffectively.
By highlighting overall poor treatment responses and similar outcomes regardless of chemotherapeutic timing in pelvic osteosarcoma, Xu and colleagues [9] imply that a personalized algorithm may be the best management. The reader may infer that variations in interventions which provide equivalent improvement of a common ailment allow treating providers to make decisions based upon optimization of secondary outcomes or avoidance of complications. In this light, Xu and colleagues [9] are not suggesting eliminating the role of preoperative chemotherapy in pelvic osteosarcoma, simply that it can be deferred if there is a reasonable advantage for early surgery in an individual patient. The adoption and utility of this approach is limited primarily by our inability to accurately predict response to chemotherapy, and ultimately would become irrelevant by the discovery of more effective systemic treatments.
How Do We Get There?
Much effort has gone into the search for more-effective systemic interventions in osteosarcoma and we need to continue these investigations. Clinical trials may involve differential treatment of good and poor responder limbs, so the information gleaned from neoadjuvant treatment is an integral part of the design and interpretation of these investigations. Despite the lack of tangible success to date, the potential to intervene positively in a welldefined at-risk population justifies the current practice of neoadjuvant chemotherapy as the standard treatment for most patients. There will be patients who do not benefit from chemotherapy, theoretically some who are even harmed by surgical delay, but ultimately this approach has the potential to provide the greatest good to the greatest number. Eventually, there will be a protocol where patients whose tumors do not respond to chemotherapy can be identified, and treatment modified to improve survival.
The solution to the problem expressed by this specific report is not to design and implement a clinical trial with the primary objective to determine the most appropriate timing of chemotherapy in pelvic osteosarcoma. The solution is to cultivate effective strategies to predict response to chemotherapy accurately and early without the need for a histologic analysis of the resected specimen. Recent strategies utilizing positron emission tomography [1] and MRI [2] are encouraging, and further elucidation, with eventual adoption, of similar techniques may determine a method where ineffective chemotherapy can be identified, and altered, early in the treatment course.
Specific reports in sarcoma always highlight the greater challenge of progress in a rare condition with so much variability in presentation and management. The more the sarcoma community can unify to share data and experiences will lessen the limitations historically stifling advancement in this unique constellation of pathology. Clinicians and institutions should be encouraged to participate in multiinstitutional clinical trials and submit tissue to tumor banks as is financially and logistically feasible. The Musculoskeletal Tumor Society has committed to creating a national sarcoma registry, which will provide a centralized database of relevant oncologic and functional outcomes, such as site of disease and response to chemotherapy, that will add to the power and understanding of future analyses.
